Non-small cell lung cancer (NSCLC) accounts for approximately 80–85% of all cases of lung
cancer, and it is the most common cause of death in men and second only to breast cancer …

Chemotherapy has reached a therapeutic plateau in the treatment of advanced non-small
cell lung cancer (NSCLC), and effective, better-tolerated treatment strategies are needed. An …

Non-small-cell lung cancer (NSCLC) is a uniformly fatal disease and most patients will
present with advanced stage. Treatment outcomes remain unsatisfactory, with low long-term …

The high morbidity and mortality of non-small cell lung cancer (NSCLC) have always been
major threats to people's health. With the identification of carcinogenic drivers in non-small …

Non‐small cell lung cancer (NSCLC) is one of the most deadly cancers worldwide, with poor
prognosis once the disease has progressed past the point at which surgery is a viable …

The search for innovative therapeutic agents in non-small cell lung cancer (NSCLC) has
witnessed a swift evolution. The number of targeted drugs that can improve patient …

The last decade has witnessed the development of oncogene-directed targeted therapies
that have significantly changed the treatment of non-small-cell lung cancer (NSCLC). In this …

Over the past decade, a multitude of targeted agents have been explored in the treatment of
advanced non–small cell lung cancer (NSCLC). Thus far, two broad classes of agents have …

Non-small-cell lung cancer (NSCLC) is characterized by wide molecular heterogeneity. In
recent years, novel agents that target specific, aberrant molecular pathways in NSCLC have …

Abstract Purpose of Review Lung cancer remains the leading cause of cancer-related
mortality worldwide. Genetic and molecular profiling of non-small cell lung cancer (NSCLC) …